Dual regulation of adenylate cyclase. A signal transduction mechanism of membrane receptors

Summary The hormone-sensitive adenylate cyclase is a multi-component system embedded in the lipid bilayer of the plasma membrane and serves as a signal transduction system for various membrane receptors. The complete system consists of various receptor molecules, which sensitize the external ligands, the effector enzyme adenylate cyclase, which catalyzes the formation of cyclic AMP from ATP, and two guanine nucleotide-binding regulatory proteins (N or G proteins), which transduce the signals from the receptors to the adenylate cyclase. Depending on the receptor type activated by a ligand, stimulatory or inhibitory, either the stimulatory or the inhibitory N protein is activated and induces stimulation or inhibition of adenylate cyclase with subsequent increase or decrease in cellular cyclic AMP levels. In this paper, the mechanisms of this hormonal signal transduction system and its regulation will be briefly reviewed, with some emphasis on the cardiac system.     

Activation of intestinal mucosal adenylate cyclase by Shigella dysenteriae I enterotoxin.

Because the mechanism whereby Shigella dysenteriae I enterotoxin induces intestinal secretion is unclear, the effect of this toxin on adenylate cyclase activity in rabbit ileal mucosa was studied under various in vitro and in vivo conditions. Activation of adenylate cyclase by Shigella enterotoxin was observed only when substrate (ATP) concentrations above the Km of adenylate cyclase were employed. These concentrations of ATP are greater than those required to demonstrate activation of adenylate cyclase by cholera toxin. Under optimal assay conditions, doses of Shigella toxin between 5.4 and 900 mug of toxin protein and in vivo incubation times between 6 and 18 hr all increased adenylate cyclase activity by about 100%. Shigella toxin produced significant but highly variable increases in mucosal cyclic AMP concentrations, which were less that the rises seen with a comparable dose of cholera toxin. This variability in cyclic AMP response to Shigella toxin and the disparity between Shigella and cholera toxins' effects on mucosal cyclic AMP are probably the result of the different kinetics of adenylate cyclase activated by these enterotoxins. Mucosal Na-K-ATPase activity was unaffected by Shigella toxin. These observations suggest that alterations in fluid and electrolyte transport induced by Shigella enterotoxin may, in part, be mediated by the adenylate cyclase-cyclic AMP system.     

Bridging of IgE receptors activates phospholipid methylation and adenylate cyclase in mast cell plasma membranes.

Bridging of IgE receptors on normal rat mast cells by divalent anti-receptor antibodies induced phospholipid methylation and an increase in intracellular cyclic AMP within 15 sec after the receptor bridging. These biochemical events were followed by Ca2+ influx and histamine release. When IgE receptors on isolated plasma membranes were bridged by the antibody, both the increase in the incorporation of [3H]methyl into lipid fraction and the synthesis of cyclic AMP were demonstrated. The synthesis of cyclic AMP in this system was enhanced in the presence of GTP. The results indicated that the bridged IgE receptors are linked to both methyltransferases and adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] in the plasma membrane. An increase in cyclic AMP prior to receptor bridging suppressed phospholipid methylation in the plasma membrane, Ca2+ uptake, and subsequent histamine release. On the other hand, inhibition of phospholipid methylation by (S)-isobutyryl-3-deazaadenosine resulted in the suppression of cyclic AMP synthesis in the plasma membrane. These findings suggest that the activation of phospholipid methylation and the activation of adenylate cyclase are e, and subsequent histamine release. On the other hand, inhibition of phospholipid methylation by (S)-isobutyryl-3-deazadenosine resulted in the suppression of cyclic AMP synthesis in the plasma membrane. These findings suggest that the activation of phospholipid methylation and the activation of adenylate cyclase are e, and subsequent histamine release. On the other hand, inhibition of phospholipid methylation by (S)-isobutyryl-3-deazadenosine resulted in the suppression of cyclic AMP synthesis in the plasma membrane. These findings suggest that the activation of phospholipid methylation and the activation of adenylate cyclase are mutually regulated.     

Resolution of adenylate cyclase sensitive and insensitive to Ca2+ and calcium-dependent regulatory protein (CDR) by CDR-sepharose affinity chromatography.

Partially purified adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] from bovine brain cortex was fractionated into two separate forms by calcium-dependent regulatory protein (CDR)-Sepharose affinity chromatography. The major form of the enzyme, comprising approximately 80% of the applied activity, did not bind to the affinity column in the presence of Ca2+ and was insensitive to the CDR. Approximately 20% of adenylate cyclase activity was absorbed to CDR-Sepharose in the presence of Ca2+. This activity was stimulated by Ca2+ and CDR. This study directly demonstrates that brain cortex contains Ca2+-CDR-sensitive and -insensitive forms of adenylate cyclase and indicates that CDR-Sepharose may be a useful tool for purification of adenylate cyclase. The Ca2+ -stimulated adenylate cyclase was purified at least 55-fold with a 13% yield.     

Phosphoinositides and calcium signaling New aspects and diverse functions in cell regulation.

Numerous circulating and locally produced hormones bind to specific cell-surface receptors and activate a variety of second-messenger pathways that evoke characteristic phenotypic responses in their target cells. One of the most ubiquitous signal transduction mechanisms is the phosphoinositide-calcium messenger system, which is activated by hormones, neurotransmitters, and growth factors. Stimulation of these receptors by their ligands causes a characteristic change in the metabolism of membrane phospholipids with production of diacylglycerol and a rapid increase in cytoplasmic Ca(2+) concentration, due to the release of stored intracellular Ca(2+) and stimulated Ca(2+) entry from the extracellular space. These intracettular signals act in concert to activate protein kinases that phosphorylate a variety of regulatory proteins. The link between phosphoinositide turnover and Ca(2+) mobilization is inositol 1,4,5-trisphosphate, the major Ca(2+)-mobilizing second messenger, which is produced from membrane phosphoinositides by activated phospholipase C enzymes. The mechanisms of ligand-regulated Ca(2+) influx and the additional regulatory role(s) of phosphoinositides and inositol phosphates are still being unfolded. This review and the following article summarize some recent developments and unsolved issues about this major signal transduction cascade that links calcium-mobilizing hormone receptors to the regulation of endocrine cell function.     

Antilipolytic effects of insulin and adenylate cyclase inhibitors on isolated human fat cells

Antilipolysis induced by insulin by adenylate cyclase inhibitors was compared in isolated human fat cells when lipolysis was activated at well-defined steps in the cyclic AMP system. The latter was achieved with isoprenaline (beta-adrenoreceptor agonist), cholera toxin and pertussis toxin (acting on the GTP-sensitive coupling proteins), forskolin (stimulating the catalytic component of adenylate cyclase), enprofylline (selective phosphodiesterase inhibitor) and N6-monobutyryl-cyclic-AMP or 8-bromo cyclic-AMP (cyclic AMP analogues which are resistant or sensitive to phosphodiesterase, respectively). Clonidine (alpha 2-adrenoreceptor agonist), prostaglandin E2 and N6-(phenylisopropyl) adenosine (adenosine analogue) failed to inhibit lipolysis stimulated by cholera toxin or pertussis toxin, but were effective under all other conditions. Insulin failed to inhibit lipolysis stimulated by enprofylline or N6-monobutyryl cyclic AMP, but was effective under all other circumstances. In conclusion, insulin and adenylate cyclase inhibitors are antilipolytic in human fat cells through different mechanisms. Adenylate cyclase inhibitors act predominantly on the GTP-sensitive coupling proteins and, to a minor extent, at some yet unidentified distal step in the lipolytic machinery. As regards insulin, the major site of the antilipolytic action is phosphodiesterase.     

Effect of protein kinase C on amylase secretion and cyclic AMP production in rat pancreatic acinar cells.

The authors examined the effects of protein kinase C on secretin-induced amylase release and cyclic AMP production in rat pancreatic acinar cells. Secretin (10(-6) M) and 12-O-tetradecanoyl-phorbol 13-acetate (TPA) (10(-6) M) induced 53% and 60% increase of amylase release from the basal level, respectively during 10 min. Simultaneous addition of TPA and secretin resulted in 42% amylase release from the basal level for 10 min. Suppression of secretin-induced amylase release was evident within 5 min of pretreatment with TPA. TPA showed the same effect on cyclic AMP production; secretin-induced increase of cyclic AMP was suppressed by pretreatment of TPA for 5 min. To explore the mechanism by which TPA inhibits secretin-induced cyclic AMP production, we also examined the effects of protein kinase C purified from rat brain on adenylate cyclase activity in pancreatic acinar membranes. Basal, forskolin- and secretin plus guanosine 5'-[gamma-thio]trisphosphate-stimulated adenylate cyclase activity were inhibited by protein kinase C in the presence of Ca++. These results suggest that protein kinase C might have a role in the inhibitory effect on adenylate cyclase in exocrine pancreas.     

Evidence for parathyroid hormone sensitive adenylate cyclase in rat glomeruli

Isolated rat glomeruli contain an adenylate cyclase system. The amount of cyclic AMP formed increased progressively with incubation time. The rate of cyclic AMP formation increased linearly with glomerular protein concentration. This adenylate cyclase system was temperature and pH dependent. There was no evidence for saturation of the enzyme with substrate up to 10^?2 M ATP. Adenylate cyclase was strikingly activated by fluoride (10^?2 M). Purified bovine parathyroid hormone (PTH) and synthetic 1–34 bovine PTH fragment both stimulated adenylate cyclase activity: maximum activity was 3.9 to 5.4 basal activity and k_m close to 10^?7 M. Epinephrine and isoproterenol produced a slight stimulation whereas salmon calcitonin, glucagon, norepinephrine and antidiuretic hormone were inactive. The demonstration of PTH activated adenylate cyclase in glomeruli raises the possibility of a role for this hormone in regulation of glomerular activity.     

Calmodulin regulation of cellular cyclic AMP production in response to arginine vasopressin, prostaglandin E2 and forskolin in rat renal papillary collecting tubule cells in culture

The effect of calmodulin on the stimulation of cyclic AMP production by arginine vasopressin (AVP), prostaglandin E2 (PGE2) and forskolin was examined in cultured renal papillary collecting tubule cells of the rat. In the presence of the phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine submaximal concentrations of AVP (1 nmol/l), PGE2 (20 nmol/l) and forskolin (240 nmol/l) significantly increased cellular cyclic AMP accumulation by 2.3-, 6.0- and 8.4-fold respectively. Two chemically dissimilar inhibitors of calmodulin, namely trifluoperazine and N-(6-amino-hexyl)-5-chloro-1-naphthalenesulphonamide (W-7), attenuated the AVP-, PGE2- and forskolin-stimulated cellular production of cyclic AMP in a dose-related manner. Cellular production of cyclic AMP was inhibited by 50% (ID50) by doses ranging from 16 to 28 mumol trifluoperazine/l and 35 to 44 mumol W-7/1. Basal accumulation of cellular cyclic AMP was also decreased by treatment with either trifluoperazine or W-7, but the effective dose was higher than that which inhibited cellular cyclic AMP production stimulated by AVP, PGE2 and forskolin. Since forskolin directly activates adenylate cyclase at a site of the catalytic unit and the cellular action of AVP to activate adenylate cyclase is mediated through receptor-guanine nucleotide regulatory-catalytic units, the present study indicates calmodulin regulation of basal, AVP-, PGE2- and forskolin-activated adenylate cyclase in the papillary collecting tubule cells.(ABSTRACT TRUNCATED AT 250 WORDS)     

Insulin secretion and action

Recent advances in insulin secretion indicate that pertussis toxin abolishes the inhibition by alpha 2 adrenoceptor activation of insulin release by the pancreas. Pertussis toxin adenosine diphosphate (ADP) ribosylates an inhibitory guanine nucleotide-binding protein (Ni) involved in inhibition of adenylate cyclase. The decrease in cyclic adenosine monophosphate (AMP) by epinephrine may account for its inhibition of insulin release. Insulin interaction with its receptor results in an increase in the tyrosine protein kinase activity of the receptor. Second messengers for insulin are generated, hexose transport is accelerated, and a cyclic AMP-independent protein kinase is activated that phosphorylates at serinethreonine residues. The activity of membrane-bound enzymes such as adenylate cyclase and Ca2+-Mg2+-ATPase is affected. The relative importance of these effects of insulin in its regulation of cellular metabolism remains to be established.     

Glucose Inhibition of Adenylate Cyclase in Intact Cells of Escherichia coli B

Previous studies in E. coli B have demonstrated an inverse correlation between the presence of glucose in the medium and the accumulation of cyclic AMP in the medium. This observation could not be explained by the action of glucose as a repressor of adenylate cyclase (EC 4.6.1.1) synthesis, as a stabilizer of cyclic AMP phosphodiesterase (EC 3.1.4.17) activity, or as a direct inhibitor of adenylate cyclase activity in cell-free preparations. The recent development of an in vivo assay for adenylate cyclase has provided a basis for further exploring the inhibitory action of glucose in intact cells. With this assay it has been possible to show that, while glucose does not affect adenylate cyclase in vitro, it rapidly inhibits the enzyme activity in intact cells. Extensive metabolism of glucose is not required, since alpha-methylglucoside also inhibits adenylate cyclase in vivo. When cells are grown on glucose as carbon source, some sugars (mannose, glucosamine) substitute for glucose as adenylate cyclase inhibitors while others (e.g., fructose) do not. Dose-response studies indicate that low concentrations of glucose lead to essentially complete inhibition of adenylate cyclase activity while only moderately decreasing intracellular cyclic AMP concentrations. The evidence presented suggests that the decreased cellular cyclic AMP levels resulting from glucose addition can be accounted for by inhibition of adenylate cyclase without any significant effect on cyclic AMP phosphodiesterase or the transport of cyclic AMP from the cells to the medium.     

ADP-induced platelet shape change and mobilization of cytoplasmic ionized calcium are mediated by distinct binding sites on platelets: 5'- p-fluorosulfonylbenzoyladenosine is a weak platelet agonist

Platelet stimulation with ADP results in several responses, including shape change, increase in cytoplasmic ionized calcium concentration [Ca2+]i, an inhibition of adenylate cyclase. 5'-p-Fluorosulphonyl benzoyladenosine (FSBA), which covalently labels an ADP binding site on platelets, blocks platelet shape change but not the inhibition of cyclic AMP levels by ADP, whereas p-chloromercuribenzenesulfonate (pCMBS), a nonpenetrating thiol reagent, has the opposite effects. We examined the effect of FSBA and pCMBS on ADP-induced increase in [Ca2+]i using platelets loaded with fluorescent Ca2+ indicators quin2 and fura-2. FSBA (50 to 200 mumol/L) induced a dose-dependent rise in [Ca2+]i, indicating that it is a weak platelet agonist. Under conditions of covalent labeling of the ADP binding sites, FSBA (50 to 100 mumol/L) did not inhibit the ADP-induced increase in [Ca2+]i or its inhibition of adenylate cyclase, whereas pCMBS (up to 1 mmol/L) abolished both these responses but not shape change. These findings suggest that ADP-induced Ca2+ mobilization and inhibition of adenylate cyclase are mediated by platelet binding sites distinct from those mediating shape change.     

Locust adipokinetic hormones: carrier-independent transport and differential inactivation at physiological concentrations during rest and flight.

Since concomitant release of structurally related peptide hormones with apparently similar functions seems to be a general concept in endocrinology, we have studied the dynamics of the lifetime of the three known adipokinetic hormones (AKHs) of the migratory locust, which control flight-directed mobilization of carbohydrate and lipid from fat body stores. Although the structure of the first member of the AKHs has been known for 20 years, until now, reliable data on their inactivation and removal from the hemolymph are lacking, because measurement requires AKHs with high specific radioactivity. Employing tritiated AKHs with high specific radioactivity, obtained by catalytic reduction with tritium gas of the dehydroLeu2 analogues of the AKHs synthesized by the solid-phase procedure, studies with physiological doses of as low as 1.0 pmol per locust could be conducted. The AKHs appear to be transported in the hemolymph in their free forms and not associated with a carrier protein, despite their strong hydrophobicity. Application of AKHs in their free form in in vivo and in vitro studies therefore now has been justified. We have studied the degradation of the three AKHs during rest and flight. The first cleavage step by an endopeptidase is crucial, since the resulting degradation products lack any adipokinetic activity. Half-lives for AKH-I, -II and -III were 51, 40, and 5 min, respectively, for rest conditions and 35, 37, and 3 min, respectively, during flight. The rapid and differential degradation of structurally related hormones leads to changes in the ratio in which they are released and therefore will have important consequences for concerted hormone action at the level of the target organ or organs, suggesting that each of the known AKHs may play its own biological role in the overall syndrome of insect flight.     

Mechanism of adenylate cyclase activation by cholera toxin: Inhibition of GTP hydrolysis at the regulatory site

Treatment of turkey erthrocyte membranes with cholera toxin caused an enhancement of the basal and catecholamine-stimulated adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] activities. Both of these activities required the presence of GTP. The toxin effect on the adenylate cyclase activity concided with an inhibition of the catecholamine-stimulated guanosinetriphosphatase activity. Inhibition of the guanosinetriphosphatase, as well as enhancement of the adenylate cyclase activity, showed the same dependence on cholera toxin concentrations, and the effect of the toxin on both activities was dependent on the presence of NAD.It is proposed that continuous GTP hydrolysis at the regulatory guanyl nucleotide site is an essential turn-off mechanism, terminating activation of the adenylate cyclase. Cholera toxin inhibits the turn-off guanosinetriphosphatase reaction and thereby causes activation of the adenylate cyclase. According to this mechanism GTP should activate the toxin-treated preparation of adenylate cyclase, as does the hydrolysis-resistant analog guanosine 5'-(beta,gamma-immino)triphosphate [Gpp(NH)p]. Indeed, the toxin-treated adenylate cyclase was maximally activated, in the presence of isoproternol, by either GTP or Gpp(NH)p, while adenylate cyclase not treated with toxin was stimulated by hormone plus GTP to only one-fifth of the activity achieved with hormone plus Gpp(NH)p. Furthermore, the toxin-treated adenylate cyclase activated by isoproterenol plus GTP remained active for and extended period (half-time of 3 min) upon subsequent addition of the beta-adrenergic blocker, propranolol. The native enzyme, however, was refractory to propranolol only if activated by Gpp(NH)p but not by GTP.     

Ion channels and the signal transduction pathways in the regulation of growth hormone secretion.

The secretion of GH from pituitary somatotrophs is mainly regulated by alterations in the levels of intracellular free Ca(2+) concentrations ([Ca(2+)](i)) that depend on the influx of Ca(2+) through voltage-gated Ca(2+) channels in the cell membrane. Hypothalamic stimulatory and inhibitory factors bind to specific receptors on the cell membrane to regulate membrane potential and activate second-messenger systems. The receptors are G-protein coupled, and activated G proteins directly influence membrane ion channels to regulate Ca(2+) influx. The function of cAMP-dependent protein kinase A is also modulated by receptor-coupled G proteins leading to the phosphorylation of Ca(2+) channel proteins and further alteration of Ca(2+) influx.     

Adenylate cyclase activity of avian granulosa: Effect of gonadotropin-releasing hormone

The activity of adenylate cyclase in crude and purified preparations of hen granulosa was investigated by measuring the production of cyclic AMP during a 20-min incubation at 30°. Both NaF and guanosine 5′-β,γ-imidotriphosphate (Gpp(NH)p), the nonhydrolyzable analog of GTP, stimulated enzyme activity in a dose-related manner. Ovine LH and, to a lesser extent, ovine FSH also activated adenylate cyclase in the presence of half-maximally stimulating concentrations of Gpp(NH)p (10^?7M). Gonadotropin-releasing hormone (10^?10–10^?4M) failed to significantly affect basal- or gonadotropin-promoted adenylate cyclase activity or the production of cyclic AMP by intact granulosa cells. Progesterone production, on the other hand, was enhanced by gonadotropin-releasing hormone (GnRH) (10^?8–10^?6M). It is suggested that in chicken granulosa cells, as in the mammalian pituitary cells, the adenylate cyclase/cyclic AMP system is not a mediator of GnRH action.     

Calcitonin gene related peptide (CGRP) activates adenylate cyclase of bovine aortic endothelial cells: guanosine 5' triphosphate dependence and partial agonist activity of a tyrosinated analogue

Human calcitonin gene related peptide (hCGRP) has been shown to release prostacyclin from cultured human endothelial cells and activate adenylate cyclase in endothelial cell membrane preparations. Human endothelial cells are difficult to obtain, so a bovine aortic endothelial cell model has been used to investigate the actions of hCGRP further. Bovine aortic endothelial cells were cultured and membranes prepared from them. In these membrane fractions there was a concentration dependent activation of adenylate cyclase by hCGRP, which required the presence of guanosine 5' triphosphate. Basal activity of adenylate cyclase was 41.5 pmol.min-1.mg-1 protein. The concentration for half maximum activation of adenylate cyclase (Kact) by hCGRP was 842 nM. The maximum increase in adenylate cyclase activity above basal in response to hCGRP was 180 pmol cyclic adenosine monophosphate.min-1.mg-1 protein. A [tyr degree] substituted analogue of hCGRP [( tyr degree]-hCGRP) also activated adenylate cyclase (Kact 2.2 microM) but the maximum stimulation by [tyr degree]-hCGRP was less than that obtained with native peptide. The same analogue partially inhibited the hCGRP dependent activation of adenylate cyclase (Ki = 2 microM). These studies show that hCGRP acts on a receptor on endothelial cells to activate adenylate cyclase and that [tyr degree]-hCGPO is a partial agonist at this receptor. The potent vasodilator properties of hCGRP may be mediated through or modified by its interaction with endothelial cells.     

Actions of growth hormone-releasing factor and somatostatin on adenylate cyclase and growth hormone release in rat anterior pituitary

The interaction of growth hormone-releasing factor (GRF) and somatostatin (SRIF) on adenylate cyclase activity and growth hormone release was investigated in pituitary homogenates and 2-day cultured rat anterior pituitary cells. GRF stimulated growth hormone release by about 3-fold (ED50 1.6 X 10(-12) M) and caused a rapid 15-fold increase in cyclic AMP production (ED50 6.0 X 10(-12) M). The increase in cyclic AMP was due to direct stimulation of adenylate cyclase by GRF, which caused a 4-fold increase in the activity of the enzyme measured in anterior pituitary homogenates. GRF-induced cyclic AMP formation and GRF-stimulated adenylate cyclase activity were maximally inhibited to the extent of about 50% by 10(-8) M somatostatin. In contrast, GRF-stimulated growth hormone release was completely inhibited by somatostatin (ID50 3.2 X 10(-11) M), suggesting a second site of action of somatostatin. These studies demonstrate that GRF stimulates growth hormone release via activation of adenylate cyclase and a rise in intracellular cyclic AMP. In addition, these findings indicate that the inhibitory action of somatostatin on growth hormone release is exerted at two levels, one at the level of adenylate cyclase affecting the production of cyclic AMP, and the other beyond the formation of the nucleotide, at a site which modulates the release of growth hormone from the cell.     

Stimulation by forskolin of the thyroid adenylate cyclase, cyclic AMP accumulation and iodine metabolism

Forskolin, a diterpene hypotensive drug, activates adenylate cyclase in brain and in some other tissues (Seamon et al., 1981). Forskolin activated adenylate cyclase in particulate preparations and enhanced cyclic AMP accumulation in slices of dog thyroid. These effects were maximal within minutes and remained constant afterwards. The action of forskolin on intact cells disappeared rapidly after washing. It reproduced two known cyclic AMP-mediated TSH effects: the activation of secretion and of protein iodination. Forskolin thus provides a very convenient tool for the study of the action of defined elevations of cyclic AMP level in thyroid cells. The activation by forskolin of adenylate cyclase was not reduced by Mn2+ which uncouples TSH and PGE1 action. This suggests that in the thyroid also, forskolin acts beyond the receptor level. The effect of forskolin on cyclic AMP accumulation was inhibited by the known negative regulators of this system in the thyroid, acetylcholine, iodide, norepinephrine, PGF1 alpha and adenosine. On the other hand, forskolin potentiated the effects of TSH, PGE1 and cholera toxin. These data show that, though it does not require the receptors for its action, forskolin does not uncouple them from the catalytic unit of adenylate cyclase.